MétaCan
Menu
Back to cohort
Record W3044885494 · doi:10.1101/2020.07.16.20155531

Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19

2020· preprint· en· W3044885494 on OpenAlexafffund
Sarah M Lofgren, Melanie R. Nicol, Ananta Bangdiwala, Katelyn A Pastick, Elizabeth C Okafor, Caleb P Skipper, Matthew F Pullen, Nicole Engen, Mahsa Abassi, Darlisha A Williams, Alanna A Nascene, Margaret L. Axelrod, Sylvain Lother, Lauren J MacKenzie, Glen Drobot, Nicole Marten, Matthew P. Cheng, Ryan Zarychanski, Ilan S. Schwartz, Michael E. Silverman, Zain Chagla, L. Kelley, Emily G. McDonald, Todd C. Lee, Kathy Huppler Hullsiek, David R. Boulware, Radha Rajasingham

Bibliographic record

VenuemedRxiv · 2020
Typepreprint
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsMcMaster UniversityUniversity of AlbertaLawson Health Research InstituteMcGill University Health CentreMcGill UniversityGeorge & Fay Yee Centre for Healthcare InnovationUniversity of Manitoba
FundersNational Institute of Mental HealthNational Institutes of HealthNorthern Alberta Clinical Trials and Research CentreMcGill University Health CentreManitoba Medical Service FoundationFogarty International CenterMcGill UniversityUniversity of MinnesotaDoris Duke Charitable Foundation
KeywordsHydroxychloroquineMedicinePlaceboNauseaAdverse effectRandomized controlled trialClinical trialAzithromycinInternal medicineVomitingCoronavirus disease 2019 (COVID-19)Alternative medicine

Abstract

fetched live from OpenAlex

INTRODUCTION: Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from three outpatient randomized clinical trials. METHODS: We conducted three randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. RESULTS: We enrolled 2,795 participants. The median age of research participants was 40 (IQR 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with placebo. The most common side effects were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths occurred. CONCLUSION: Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can safely investigate whether hydroxychloroquine is efficacious for COVID-19.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.419
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.412
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0070.419
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.002
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.353
GPT teacher head0.538
Teacher spread0.185 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2020
Admission routes2
Has abstractyes

Explore more

Same venuemedRxivSame topicCOVID-19 Clinical Research StudiesFrench-language works237,207